Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Giant cell tumours; Lung cancer; Non-small cell lung cancer; Pulmonary blastoma
- Focus Therapeutic Use
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 10 May 2017 Status changed from not yet recruiting to recruiting.
- 19 Jan 2017 New trial record